Speaker(s): 

Jacob Laser, MD, Staff Member, Geisinger - has nothing to disclose.

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• evaluate the effect of a single course of Rituximab on the probability of relapse in Anti NMDAR Encephalitis
• assess how this protection holds up over time

Questions to consider:

• what is the mechanism of action of Tiruximab?
• what other medications are used in the secondary prevention of Anti NMDAR encephalitis?
• what future studies could be helpful in evaluating the effectiveness of Rituximab for this indication?

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Emily Sun, DO and Cortney Houtz, LPN have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

1. Why do current AHA/ASA guidelines recommend against prophylactic ASMs after stroke — and does that mean we have proven they are harmful, or simply that we lack evidence?
2. The trial's primary endpoint included death and dropout, not just seizures. What problem does this create when trying to answer the question "does ESL prevent epilepsy?
3. ESL was given for only 30 days, but epileptogenesis after stroke unfolds over weeks to months. Does a 30-day treatment window make biological sense — and if not, what would you change?